National Planning Corp raised its stake in shares of bluebird bio, Inc. (NASDAQ:BLUE) by 11.8% during the second quarter, Holdings Channel reports. The institutional investor owned 4,910 shares of the biotechnology company’s stock after buying an additional 520 shares during the period. National Planning Corp’s holdings in bluebird bio were worth $517,000 as of its most recent filing with the SEC.

Several other institutional investors have also added to or reduced their stakes in BLUE. Pictet Asset Management Ltd. raised its position in bluebird bio by 26.2% in the first quarter. Pictet Asset Management Ltd. now owns 182,841 shares of the biotechnology company’s stock valued at $16,620,000 after buying an additional 37,925 shares in the last quarter. Bank of New York Mellon Corp raised its position in bluebird bio by 10.7% in the first quarter. Bank of New York Mellon Corp now owns 228,663 shares of the biotechnology company’s stock valued at $20,787,000 after buying an additional 22,011 shares in the last quarter. Advisors Asset Management Inc. acquired a new position in bluebird bio during the first quarter valued at approximately $858,000. Commerzbank Aktiengesellschaft FI acquired a new position in bluebird bio during the first quarter valued at approximately $588,000. Finally, Usca Ria LLC acquired a new position in bluebird bio during the first quarter valued at approximately $707,000.

Shares of bluebird bio, Inc. (NASDAQ BLUE) opened at 93.95 on Friday. bluebird bio, Inc. has a 52-week low of $37.05 and a 52-week high of $123.75. The stock’s market capitalization is $4.28 billion. The stock has a 50 day moving average of $98.52 and a 200 day moving average of $90.12.

bluebird bio (NASDAQ:BLUE) last posted its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.73) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.66) by $0.07. The company had revenue of $16.70 million during the quarter, compared to the consensus estimate of $6.29 million. bluebird bio had a negative return on equity of 32.19% and a negative net margin of 1,080.59%. The company’s revenue for the quarter was up 977.4% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.59) earnings per share. Analysts forecast that bluebird bio, Inc. will post ($6.78) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This report was reported by Daily Political and is the sole property of of Daily Political. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.dailypolitical.com/2017/08/13/national-planning-corp-acquires-520-shares-of-bluebird-bio-inc-nasdaqblue.html.

A number of equities research analysts have issued reports on the stock. BidaskClub raised shares of bluebird bio from a “buy” rating to a “strong-buy” rating in a report on Friday, June 23rd. Wedbush reissued an “outperform” rating and issued a $100.00 price target (down previously from $121.00) on shares of bluebird bio in a report on Friday, June 23rd. Morgan Stanley reissued an “equal weight” rating and issued a $105.00 price target (up previously from $91.00) on shares of bluebird bio in a report on Wednesday, June 14th. Cowen and Company reissued a “buy” rating on shares of bluebird bio in a report on Friday, June 23rd. Finally, Cantor Fitzgerald set a $39.00 price target on shares of bluebird bio and gave the stock a “sell” rating in a report on Saturday, June 24th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $100.66.

In other news, insider Eric Sullivan sold 861 shares of the company’s stock in a transaction dated Friday, August 4th. The shares were sold at an average price of $93.83, for a total value of $80,787.63. Following the transaction, the insider now directly owns 5,924 shares in the company, valued at $555,848.92. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Philip D. Gregory sold 750 shares of the company’s stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $99.00, for a total transaction of $74,250.00. Following the completion of the transaction, the insider now owns 31,234 shares in the company, valued at $3,092,166. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 77,856 shares of company stock worth $8,093,145. Company insiders own 3.90% of the company’s stock.

bluebird bio Company Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio, Inc. (NASDAQ:BLUE).

Institutional Ownership by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.